Experimental ASXL1 ‐Mediated Clonal Hematopoiesis Promotes Inflammation and Accelerates Heart Failure

HomeJournal of the American Heart AssociationVol. 11, No. 19Experimental ASXL1‐Mediated Clonal Hematopoiesis Promotes Inflammation and Accelerates Heart Failure Open AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citations ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toOpen AccessLetterPDF/EPUBExperimental ASXL1‐Mediated Clonal Hematopoiesis Promotes Inflammation and Accelerates Heart Failure Kyung‐Duk Min, MD, PhD, Ariel H. Polizio, PhD, Anupreet Kour, PhD, Mark C. Thel, BA and Kenneth Walsh, PhD Kyung‐Duk MinKyung‐Duk Min , Hematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, , University of Virginia School of Medicine, , Charlottesville, , VA, Search for more papers by this author , Ariel H. PolizioAriel H. Polizio , Hematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, , University of Virginia School of Medicine, , Charlottesville, , VA, Search for more papers by this author , Anupreet KourAnupreet Kour , Hematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, , University of Virginia School of Medicine, , Charlottesville, , VA, Search for more papers by this author , Mark C. ThelMark C. Thel , Hematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, , University of Virginia School of Medicine, , Charlottesville, , VA, Search for more papers by this author and Kenneth WalshKenneth Walsh *Correspondence to: Kenneth Walsh, PhD, Hematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, 415 Lane Rd, Charlottesville, VA 22908. Email: E-mail Address: [email protected] https://orcid.org/0000-0001-7580-2276 , Hematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, , University of Virginia School of Medicine, , Charlottesville, , VA, Search for more papers by this author Originally published21 Sep 2022https://doi.org/10.1161/JAHA.122.026154Journal of the American Heart Association. 2022;11:e026154Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: September 21, 2022: Ahead of Print Clonal hematopoiesis is a hallmark of aging, and its associations with cardiovascular diseases have been documented in multiple human cohorts.1 Heart failure is a leading cause of death, particularly in older adults, and its relationship with clonal hematopoiesis has been elaborated by a series of epidemiological and experimental studies. Recently, Yu et al reported that incident heart failure is associated with clonal hematopoiesis in an analysis of 56 597 individuals from 5 study cohorts.2 It was found that prevalent somatic mutation variants of TET2, JAK2, and ASXL1, commonly referred to as clonal hematopoiesis “driver” genes, are individually associated with an increased risk of developing heart failure. Furthermore, subgroup analysis revealed that only mutations in ASXL1 were associated with reduced left ventricular ejection fraction. While prior experimental studies have provided mechanistic evidence for causal relationships between various clonal hematopoiesis driver genes and heart failure,1 the relationship between left ventricular dysfunction and variants in ASXL1 has not been previously evaluated by mechanistic experiments.The authors will make the data, methods used in the analysis, and materials used to conduct the research available to any researcher for purposes of reproducing the results or replicating the procedures used in this publication. Additional supporting data are available from the corresponding author upon reasonable request. All procedures involving animal subjects have been approved by the Institutional Animal Care and Use Committee at the University of Virginia under Walsh protocol 4205. Mice heterozygous for the knock‐in Asxl1 p.G643WfsX12 (Asxl1tm/+) mutation, which gives rise to a truncated protein, were used in these studies because the mutation is physiologically expressed by its native promoter and this model mimics the most frequently detected mutations in the human ASXL1 driver gene (Figure A).3To test the hypothesis that ASXL1‐mediated clonal hematopoiesis contributes to heart failure and left ventricular dysfunction, we established a murine model using chest‐shielded bone marrow transplantation (BMT) to eliminate the potential effects of radiation‐induced cardiac tissue damage (Figure B). After irradiation, recipient mice were transplanted with bone marrow cells from either Asxl1tm/+ or littermate wild‐type mice, and hematopoietic and cardiac parameters were assessed as described previously.4 Consistent with the clinical paradigm of clonal hematopoiesis, BMT with Asxl1tm/+ donor cells did not lead to alterations in levels of hematopoietic stem and progenitor cells subpopulations, white blood cells, hemoglobin, or platelets, and did not affect red blood cell distribution width or spleen weight (Figure C). Consistent with previous studies,3 the BMT of CD45.2, Asxl1tm/+ donor cells did not show competitive expansion in white blood cells compared with wild‐type (Figure D). Donor cell engraftment was 52.5±9.8% in white blood cells at 6 weeks after BMT, representing a mutant allele fraction of 26% that is within the range observed in clonal hematopoiesis carriers. Following left anterior descending (LAD) artery ligation, mice showed a trend toward greater mortality in the Asxl1tm/+ group compared with the control group (Figure E). Echocardiographic analysis of surviving animals showed that, at 28 days after LAD artery ligation, the group that underwent Asxl1tm/+ BMT displayed significantly lower left ventricular ejection fraction compared with the control group (Figure F), and this was accompanied by the infiltration of CD45.2 leukocytes, greater macrophage infiltration, and more reactive fibrosis of the left ventricle (Figure G and H). To extend these results to a model of nonischemic heart failure, a separate set of control and test mice were infused with a supraphysiological dose of angiotensin II to induce cardiac damage from persistent, uncontrolled hypertension. The Asxl1tm/+‐transplanted group of mice displayed greater left ventricular systolic dysfunction by 56 days and a trend toward greater cardiac dysfunction by 28 days (Figure I). Collectively, these findings provide evidence for a causal relationship between ASXL1‐mediated clonal hematopoiesis and heart failure.Download figureDownload PowerPointFigure 1. Experimental system and consequences of hematopoietic Asxl1 mutagenesis.A, Schematic of the knock‐in Asxl1 allele. The insertion of a guanine nucleotide generates a premature stop codon resulting in a truncated protein at exon 13. B, Schematic of the experimental design using chest‐shielded BMT. B6 CD45.1 Pep Boy recipient animals were irradiated with 2 radiation doses of 5.5 Gy 4 h apart using a lead shield to protect the heart from radiation injury. Mice received 4×106 (for chimerism analysis) or 8×106 (for experimental heart failure models) bone marrow cells from C57BL/6J wild‐type or Asxl1tm/+ mice. C, Hematopoietic cell parameters and spleen weights of mice transplanted with Asxl1tm/+ and littermate wild‐type bone marrow at 8 weeks post‐BMT. Cells were analyzed by flow cytometry and an Element HT5 Veterinary Hematology Analyzer.4 Statistical significance was evaluated by multiple Student t test (hematopoietic stem and progenitor cells) or by 2‐tailed unpaired Student t test (others). D, The chimerism of transplanted CD45.2 cells was analyzed by flow cytometry at indicated time points (n=5 per genotype). Statistical significance was evaluated by a 2‐way repeated‐measures ANOVA. E and F, 6 weeks after chest‐shielded BMT, LAD ligation was performed. E, The Kaplan–Meier curve shows survival after LAD ligation. The mortality rates of the wild‐type mice and Asxl1tm/+ mice after surgery were 13.6% and 41.0%, respectively, during the follow‐up period. An exact log‐rank test was used for statistical analysis. F, Echocardiographic evaluation at 28 days after LAD artery ligation on surviving mice to assess ejection fraction (n=19 for wild‐type and n=13 for Asxl1tm/+, respectively). Ejection fraction was calculated from parasternal long‐axis view in VevoLab, which utilizes modified Simpson's biplane method of disk summation. The statistical test was 2‐way repeated‐measures ANOVA. G, Masson’s trichrome staining quantification of left ventricle fibrosis area. (n=4 for wild‐type and n=6 for Asxl1tm/+, respectively; mean±SEM; Mann–Whitney U test). H, Quantification of positive MAC3+ macrophages and CD45.2 cells in heart after LAD ligation by immunofluorescence staining of paraffin sections (n=4 mice; 10 fields of view per mouse; mean±SEM; *P<0.05, Mann–Whitney U test). I, Sequential analysis of echocardiographic analysis shows the effect of Asxl1tm/+ BMT on fractional shortening before the infusion (Day 0) of angiotensin II (2.0 mg/kg per day) (n=11 for wild‐type and n=12 for Asxl1tm/+), and after 28 and 58 days. The statistical test was by 2‐way repeated‐measures ANOVA. J, Cytokine transcript expression by cardiac macrophages isolated from mice transplanted with wild‐type or Asxl1tm/+ bone marrow. CD64+ macrophages were sorted by flow cytometry after 58 days of angiotensin II infusion. K, Cytokine expression by peritoneal macrophages isolated from wild‐type and Asxl1tm/+ mice. Elicited peritoneal macrophages were stimulated with 10 ng/mL lipopolysaccharide and 2 ng/mL interferon‐γ for 6 h and transcript expression was analyzed by quantitative reverse transcription polymerase chain reaction. Statistical significance was evaluated by 2‐tailed unpaired Student t tests. BMT indicates bone marrow transplantation; CMP, common myeloid progenitor; EF, ejection fraction; FS, fractional shortening; GMP, granulocyte‐monocyte progenitor; HGB, hemoglobin; LSK, Lin−Sca‐1+c‐Kit+ cells; LT‐HSC, long‐term hematopoietic stem cells; MEP, megakaryocyte‐erythrocyte progenitor; MMP, multipotent progenitors; ns, not significant; PLT, platelet; RDW, red blood cell distribution width; ST‐HSC, short‐term hematopoietic stem cells; SW, spleen weight; TL, tibial length; tm, truncating mutation; WBC, white blood cells; and WT, wild‐type. *P<0.05; **P<0.01; ***P<0.001.Many clonal hematopoiesis driver gene candidates are believed to promote heart failure through pro‐inflammatory mechanisms involving inflammasome activation and cytokine overproduction by myeloid cells.1 Thus, we tested whether the Asxl1 variant could also confer a pro‐inflammatory phenotype to macrophages. At the termination of the AngII infusion experiment, cardiac macrophages isolated from mice transplanted with Asxl1tm/+ bone marrow expressed higher levels of the transcripts that encode for IL‐1β and IL‐6 among a group of representative cytokines involved in cardiac inflammation (Figure J). Similarly, peritoneal macrophages harvested from Asxl1tm/+ mice and littermate wild‐type animals expressed higher levels of Il1b and Il6 following incubation with lipopolysaccharide and interferon‐γ (Figure K), consistent with previous findings on TET2 variants and other clonal hematopoiesis driver genes.1, 4, 5 Because the link between IL‐1β and IL‐6 cytokines and prognosis in patients with heart failure has been well documented,1 these data support a mechanism of accelerated heart failure caused by elevated cytokine production that results from ASXL1‐mediated clonal hematopoiesis.Sources of FundingThis work was funded by National Institutes of Health (Bethesda, MD) grants AG073249, HL141256, HL152174, and HL139819. There are no relationships with industry to report.DisclosuresNone.AcknowledgmentsThe Asxl1 pG643WfsX12 mouse strain was kindly provided by Dr Wen‐Chien Chou in National Taiwan University College of Medicine. We thank Heather Doviak for assistance with these experiments.Footnotes*Correspondence to: Kenneth Walsh, PhD, Hematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, 415 Lane Rd, Charlottesville, VA 22908. Email: [email protected]eduFor Sources of Funding and Disclosures, see page 3.References1 Min KD, Kour A, Sano S, Walsh K. The role of clonal haematopoiesis in cardiovascular diseases: epidemiology and experimental studies. J Intern Med.2020; 288:507–517. doi: 10.1111/joim.13130CrossrefMedlineGoogle Scholar2 Yu B, Roberts MB, Raffield LM, Zekavat SM, Nguyen NQH, Biggs ML, Brown MR, Griffin G, Desai P, Correa A, et al; National Heart, Lung, and Blood Institute TOPMed Consortium . Supplemental association of clonal hematopoiesis with incident heart failure. J Am Coll Cardiol.2021; 78:42–52. doi: 10.1016/j.jacc.2021.04.085CrossrefMedlineGoogle Scholar3 Hsu YC, Chiu YC, Lin CC, Kuo YY, Hou HA, Tzeng YS, Kao CJ, Chuang PH, Tseng MH, Hsiao TH, et al.The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock‐in mouse model. J Hematol Oncol.2017; 10:139. doi: 10.1186/s13045‐017‐0508‐xCrossrefMedlineGoogle Scholar4 Sano S, Oshima K, Wang Y, MacLauchlan S, Katanasaka Y, Sano M, Zuriaga MA, Yoshiyama M, Goukassian D, Cooper MA, et al. Tet2‐mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL‐1beta/NLRP3 inflammasome. J Am Coll Cardiol.2018; 71:875–886. doi: 10.1016/j.jacc.2017.12.037CrossrefMedlineGoogle Scholar5 Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu CL, Sano S, Muralidharan S, Rius C, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science.2017; 355:842–847. doi: 10.1126/science.aag1381CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails October 4, 2022Vol 11, Issue 19Article InformationMetrics Copyright © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley BlackwellThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.https://doi.org/10.1161/JAHA.122.026154PMID: 36129058 Manuscript receivedMarch 16, 2022Manuscript acceptedAugust 29, 2022Originally publishedSeptember 21, 2022 Keywordscause of deathstroke volumeleftcardiovascular diseasesclonal hematopoiesisagedventricular functionagingPDF download SubjectsHeart FailureInflammatory Heart Disease